Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Ibrutinib produces high response rates and durable remissions in Waldenström macroglobulinemia (WM) that are impacted by MYD88 and CXCR4(WHIM) mutations. Disease progression can develop on ibrutinib, although the molecular basis remains to be clarified. We sequenced sorted CD19(+) lymphoplasmacytic...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Xu, Lian, Tsakmaklis, Nicholas, Yang, Guang, Chen, Jiaji G., Liu, Xia, Demos, Maria, Kofides, Amanda, Patterson, Christopher J., Meid, Kirsten, Gustine, Joshua, Dubeau, Toni, Palomba, M. Lia, Advani, Ranjana, Castillo, Jorge J., Furman, Richard R., Hunter, Zachary R., Treon, Steven P.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2017
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484977/
https://ncbi.nlm.nih.gov/pubmed/28235842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-01-761726
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker